초록 ▼

The invention is directed to fibrin materials for use in fibrin compositions and methods that avoid the need to use thrombin as an activating agent for fibrin monomer-based sealants. The invention provides for substantially pure fibrin chains, fibrin chain precursors, fibrin chains with other N-term

The invention is directed to fibrin materials for use in fibrin compositions and methods that avoid the need to use thrombin as an activating agent for fibrin monomer-based sealants. The invention provides for substantially pure fibrin chains, fibrin chain precursors, fibrin chains with other N-terminal extensions, fibrin monomer, fibrin-homolog and fibrin-analog. The invention further provides for variant fibrin .gamma.-chains. The variant gamma-chain contains one or more mutations and/or deletions in the C-terminal region following the coiled-coil forming region such that, when incorporated into fibrin-homolog, the homolog lacks the ability to self-polymerize but has the ability to form non-covalent bonds, and thereby form mixed polymers useful as sealants, with fibrinogen. The invention also provides nucleotide sequences encoding fibrin chains or fibrin chain variants and cells expressing fibrin chains, fibrin chain variants, fibrin monomer, fibrin precursor or fibrinogen-analog. The invention further provides a method of forming fibrin-related proteins in vitro from their component fibrin chains. The invention additionally provides a method for forming a fibrin sealant by a reacting a first fibrin-related protein that is incapable of self-polymerizing with a second fibrin-related protein that is incapable of self-polymerizing. Fibrin chains produced by methods of the present invention may be used as sources of substantially pure starting material for the production of important fibrin-derived factors that regulate angiogenesis, platelet aggregation, and other physiological processes.

대표청구항 ▼

[ What is claimed is:] [1.] A fibrin sealant comprising human fibrin-homolog, wherein said human fibrin-homolog comprises recombinant variant fibrin gamma-human comprising:recombinant variant fibrin gamma-chain that differs from naturally occurring human fibrin gamma-chain by one or more mutations o

[ What is claimed is:] [1.] A fibrin sealant comprising human fibrin-homolog, wherein said human fibrin-homolog comprises recombinant variant fibrin gamma-human comprising:recombinant variant fibrin gamma-chain that differs from naturally occurring human fibrin gamma-chain by one or more mutations or deletions in a C-terminal region following a coiled-coil forming region such that when incorporated into fibrin-homolog, the homolog lacks the ability to substantially self-polymerize but has the ability to form non-covalent bonds and thereby polymerize with fibrinogen.